Details
CJC1296 with DAC
CAS 863288-34-0
2mg/vial
CJC1295 DAC has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC-1295 shown the ability to increase growth hormone and IGF-I secretion and its benefits, but it has been able to do so in very large amounts. Recent research studies have shown that CJC - 1295 stimulates GH and IGF-1 Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to intense fat loss, and increases protein synthesis.
CAS No.: 863288-34-0
MF: C159H258N46O45
MW: 3647.15
Type:: Pharmaceutical Intermediates
Purity: 98% white CJC1295 powder
Packing: plastic vial(dedicated for peptide packing) or glass vial, quantity according to customer's detail requirement.
Storage: a cool(2~8 ℃) & dry place protected from light, keep package close when not in use.
2. CJC-1295 with DAC Specification:
Appearance : White powder
Specific Optical Rotation (c=0.5,10% HAc) :-50.0~-60.0°
Water Content(Karl Fischer) : ≤5.0%
Acetate Content(by HPLC) : ≤15.0%
Amino Acid Composition :±10% of theoretical
Purity(by HPLC) : ≥98.0%
Single Impurity(by HPLC) : ≤1.0%
Peptide Content(by %N) : ≥80%
Assay(By Anhydrous, Acetic Acid-free ) : 95.0~105.0%
Bacterial Endotoxins : ≤5EU/mg
Related attributes of Cjc-1295 with Dac (2mg/vial 10vials/kit)
3. CJC-1295 with DAC Application:
CJC-1295 DAC has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC-1295 shown the ability to increase growth hormone and IGF-I secretion and its benefits, but it has been able to do so in very large amounts. Recent research studies have shown that CJC - 1295 stimulates GH and IGF-1 Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to intense fat loss, and increases protein synthesis.
4. CJC-1295 with DAC Acting Growth Hormone Releasing Hormone:
It is a long acting Growth Hormone Releasing Hormone, which causes the anterior pituitary to release more growth hormone. GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin (growth-hormone inhibiting-hormone). Clinical Research was first conducted for CJC-1295 during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous hgH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects. Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse. Studies shows that combining a GHRP-6 with CJC 1295 DAC, significantly increase the release of GH and IGF-1 production without an increase in prolactin. An example of a GHRP (GH Releasing Peptide) is Hexarelin or GHRP-2. CJC 1295 DAC is a exceptionally designed peptide and is known for being the finest of the hGH secretogues. The DAC (Drug Affinity Complex) portion increases the half-life by binding with serum albumin and protects the CJC-1295 DAC peptide from degradation. This was formed when a lysine link was bounded to DACs to a reactive chemical called maleimidoproprionic acid (MPA).
China (Mainland)